Why the study?
The authors aimed to expand the treatment indications in the 2021 ESC guidelines with subsequent findings to improve clinical understanding and inform future guideline editions.
Population
46 selected clinical trials and randomized controlled trials
Design
Systematic literature review
Key result
Recent ESC 2021 guidelines and new clinical studies highlight the efficacy of novel therapies like SGLT2 inhibitors and ARNI, as well as the importance of early risk prediction using biomarkers in managing acute and chronic heart failure.
Authors
Loading...
Supports integration of SGLT2 inhibitors, ARNI, and biomarkers into heart failure care; extends ESC 2021 guidelines with updated trial evidence.
Systematic Review
This systematic review summarizes recent clinical trial evidence to expand upon the ESC 2021 heart failure guidelines, emphasizing the integration of SGLT2 inhibitors, vericiguat, and novel biomarkers into clinical practice.
Perrotta Giulio (2022) conducted a systematic review in Heart Failure. Recent innovations in clinical therapy (e.g., SGLT2 inhibitors, ARNI, biomarkers) was evaluated. Recent ESC 2021 guidelines and new clinical studies highlight the efficacy of novel therapies like SGLT2 inhibitors and ARNI, as well as the importance of early risk prediction using biomarkers in managing acute and chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: